BioMarin Pharmaceutical Inc. diskutieren
BioMarin Pharmaceutical Inc.
WKN: 924801 / Symbol: BMRN / Name: BioMarin Pharmaceutical / Aktie / Pharmazeutika / Large Cap /
73,64 €
-4,56 %
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $125.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Stifel Nicolaus from $114.00 to $118.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. They now have a $102.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Truist Financial Co. from $125.00 to $140.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "outperform" rating re-affirmed by analysts at Robert W. Baird. They now have a $127.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $120.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Stifel Nicolaus from $118.00 to $108.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Morgan Stanley from $129.00 to $125.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $120.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $110.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $140.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $140.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $120.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $100.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $101.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Robert W. Baird from $127.00 to $104.00. They now have an "outperform" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $100.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Piper Sandler from $115.00 to $107.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Wells Fargo & Company from $100.00 to $110.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
Neueste Beiträge
Morgan_Stanley in Cinemark Holdings Inc. diskutieren